Teva Pharmaceutical Industries (TEVA) Expected to Release Quarterly Earnings on Tuesday

Key Points

• Teva is expected to report Q3 2026 results before Tuesday’s market open, with analysts forecasting earnings of $0.72 per share and revenue of $4.24 billion. The earnings call is scheduled for November 3 at 8:00 a.m. ET.
• TEVA shares recently traded at $39.93, near their 12-month high of $42.02, while the stock has gained substantially above its 200-day moving average. Analysts maintain a “Moderate Buy” consensus with an average price target of $46.08.
• Analyst views are mixed: TD Cowen, Oppenheimer and Barclays raised or initiated positive ratings, while Zacks downgraded the stock to “strong sell.” Insiders sold roughly 375,000 shares worth $14.6 million over the past 90 days.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Teva Pharmaceutical Industries to announce earnings of $0.72 per share and revenue of $4.24 billion for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. On average, analysts expect Teva Pharmaceutical Industries to post $2.00 EPS for the current fiscal year and $3.04 EPS for the next fiscal year.

Teva Pharmaceutical Industries Trading Up 1.3%

NYSE TEVA opened at $39.93 on Tuesday. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. The firm's fifty day moving average price is $38.75 and its 200 day moving average price is $34.38. The company has a market capitalization of $46.53 billion, a price-to-earnings ratio of 66.54, a price-to-earnings-growth ratio of 3.66 and a beta of 0.89. Teva Pharmaceutical Industries has a 12 month low of $19.00 and a 12 month high of $42.02.

Analysts Set New Price Targets

Several analysts have recently weighed in on TEVA shares. Zacks Research downgraded Teva Pharmaceutical Industries from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 20th. Wall Street Zen lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. TD Cowen started coverage on Teva Pharmaceutical Industries in a research report on Thursday, October 1st. They set a "buy" rating and a $55.00 price target on the stock. Oppenheimer increased their price objective on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an "outperform" rating in a report on Friday, October 9th. Finally, Barclays raised their target price on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an "overweight" rating in a research report on Thursday, October 15th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $46.08.

Insider Buying and Selling

In other news, Director Roberto Mignone sold 367,600 shares of the firm's stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $39.06, for a total value of $14,358,456.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider owned 8,500 shares in the company, valued at approximately $330,225. This trade represents a 46.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 374,959 shares of company stock worth $14,644,285 in the last ninety days. 0.54% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world's largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva's portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.